Computer-Generated Vs. Standard Informed Consent for HIV Research Studies

NCT ID: NCT00104559

Last Updated: 2008-09-26

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

40 participants

Study Classification

INTERVENTIONAL

Study Start Date

2005-01-31

Study Completion Date

2009-03-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to test an interactive multimedia informed consent (iMIC) computer program to see if the program can generate a consent form that potential participants in an HIV trial can understand. This study will also determine if these participants prefer the computer-generated consent form and associated interactive tools to a standard consent form written by researchers.

Study hypothesis: 1) Participants who receive information about clinical trials from iMIC Consent Tutorials will answer more questions about the trial correctly than participants who receive information about clinical trials from standard paper consent forms. 2) Participants will rate the iMIC Consent Tutorials as having better usability and user satisfaction than standard paper consent forms.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Researchers conducting clinical trials have a legal and ethical obligation to provide participants key information about the trial so that they may either decline participation or grant their informed consent to participate in the study. However, information provided to prospective clinical trial participants is often complex and confusing; often, language used in informed consent is written far above participants' reading level. This study will evaluate the usefulness of a consent form authoring system that helps researchers write comprehensive and understandable consent forms; the authoring system produces both paper consent forms and interactive computer tutorials that are designed to teach potential volunteers about the research study they are considering. This study will compare iMIC-generated consent forms and computer tutorials with standard consent forms for two mock HIV studies: a vaccine trial (VT) and an antiretroviral drug trial (AT).

The iMIC software provides researchers a computer-based authoring environment for producing easier-to-understand informed consent documents. iMIC assists researchers by helping them focus on clearly defining consent issues and content goals, including regulatory, legal, and ethical guidelines to be followed. Through tests for readability and other feedback, iMIC ensures that all the content requirements of good informed consent are met. iMIC generates a paper consent form and an interactive multimedia computer tutorial to help volunteers learn about the clinical trial. The paper consent document can be stand alone or used in conjunction with the generated computer tutorial.

Each participant will receive two consent interventions: one computer-based tutorial and one standard paper consent form. Participants will be randomly assigned to one of four groups. Group 1 will receive the computer-based tutorial for VT and then the standard paper consent form for AT. Group 2 will receive the standard paper consent form for VT and then the computer-based tutorial for AT. Group 3 will receive the computer-based tutorial for AT and then the standard paper consent form for VT. Group 4 will receive the standard paper consent form for AT and then the computer-based tutorial for VT.

At the start of the session, participants will be asked demographic questions and will receive the first consent intervention. When they have completed the intervention, they will be asked 15 questions about the key elements of the clinical trial they have just learned about, as well as an additional series of usability and satisfaction questions about the consent intervention. Next, they will receive the second consent intervention that will teach them about the second clinical trial. Again, they will be asked knowledge and usability and satisfaction questions. After completing the second consent intervention, participants will be asked to compare and answer questions about the two methods of receiving information about clinical trials.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

HIV Infections

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

HIV Informed Consent

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

1

Participants will receive the computer-based tutorial for VT and then the standard paper consent form for AT

Group Type EXPERIMENTAL

iMIC-generated consent form and tutorial

Intervention Type BEHAVIORAL

Computer-based consent form and tutorial

Standard paper consent form

Intervention Type BEHAVIORAL

Standard paper consent form

2

Participants will receive the standard paper consent form for VT and then the computer-based tutorial for AT

Group Type EXPERIMENTAL

iMIC-generated consent form and tutorial

Intervention Type BEHAVIORAL

Computer-based consent form and tutorial

Standard paper consent form

Intervention Type BEHAVIORAL

Standard paper consent form

3

Participants will receive the computer-based tutorial for AT and then the standard paper consent form for VT

Group Type EXPERIMENTAL

iMIC-generated consent form and tutorial

Intervention Type BEHAVIORAL

Computer-based consent form and tutorial

Standard paper consent form

Intervention Type BEHAVIORAL

Standard paper consent form

4

Participants will receive the standard paper consent form for AT and then the computer-based tutorial for VT

Group Type EXPERIMENTAL

iMIC-generated consent form and tutorial

Intervention Type BEHAVIORAL

Computer-based consent form and tutorial

Standard paper consent form

Intervention Type BEHAVIORAL

Standard paper consent form

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

iMIC-generated consent form and tutorial

Computer-based consent form and tutorial

Intervention Type BEHAVIORAL

Standard paper consent form

Standard paper consent form

Intervention Type BEHAVIORAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* HIV-infected OR at risk for HIV infection
* Able to read English at the 5th grade level
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

The Circumplex Company

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Brian D. Raffety, PhD

Role: PRINCIPAL_INVESTIGATOR

The Circumplex Company

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

The Circumplex Company

Seattle, Washington, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

1R43AI058870-01

Identifier Type: NIH

Identifier Source: secondary_id

View Link

1R43AI058870-01

Identifier Type: NIH

Identifier Source: org_study_id

View Link